Ryvu Therapeutics SA (RVU) - Total Liabilities
Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has total liabilities worth zł159.63 Million PLN (≈ $43.93 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Ryvu Therapeutics SA to track the company's year-over-year net asset growth rate.
Ryvu Therapeutics SA - Total Liabilities Trend (2010–2025)
This chart illustrates how Ryvu Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. See Ryvu Therapeutics SA (RVU) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Ryvu Therapeutics SA Competitors by Total Liabilities
The table below lists competitors of Ryvu Therapeutics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TK Chemical Corporation
KQ:104480
|
Korea | ₩266.44 Billion |
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
Sweden | Skr53.87 Million |
|
LI Ming Development Construction Co Ltd
TWO:6212
|
Taiwan | NT$7.36 Billion |
|
GREEN CROSS WellBeing Corporation
KQ:234690
|
Korea | ₩126.28 Billion |
|
MCOT Public Company Limited
F:OLU1
|
Germany | €3.74 Billion |
|
Phinergy Ltd
TA:PNRG
|
Israel | ILA15.07 Million |
|
Team Precision Public Company Limited
BK:TEAM
|
Thailand | ฿767.61 Million |
|
Shun On Electronic Co Ltd
TW:6283
|
Taiwan | NT$688.59 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Ryvu Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Ryvu Therapeutics SA.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ryvu Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ryvu Therapeutics SA (2010–2025)
The table below shows the annual total liabilities of Ryvu Therapeutics SA from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł170.60 Million ≈ $46.95 Million |
-27.37% |
| 2024-12-31 | zł234.89 Million ≈ $64.65 Million |
+63.56% |
| 2023-12-31 | zł143.61 Million ≈ $39.52 Million |
+9.14% |
| 2022-12-31 | zł131.59 Million ≈ $36.21 Million |
+121.55% |
| 2021-12-31 | zł59.39 Million ≈ $16.35 Million |
-17.42% |
| 2020-12-31 | zł71.92 Million ≈ $19.79 Million |
+13.92% |
| 2019-12-31 | zł63.13 Million ≈ $17.38 Million |
+3.77% |
| 2018-12-31 | zł60.84 Million ≈ $16.74 Million |
+53.72% |
| 2017-12-31 | zł39.58 Million ≈ $10.89 Million |
+18.46% |
| 2016-12-31 | zł33.41 Million ≈ $9.19 Million |
+81.95% |
| 2015-12-31 | zł18.36 Million ≈ $5.05 Million |
+4.63% |
| 2014-12-31 | zł17.55 Million ≈ $4.83 Million |
+18.19% |
| 2013-12-31 | zł14.85 Million ≈ $4.09 Million |
+51.28% |
| 2012-12-31 | zł9.82 Million ≈ $2.70 Million |
+62.45% |
| 2011-12-31 | zł6.04 Million ≈ $1.66 Million |
-31.08% |
| 2010-12-31 | zł8.77 Million ≈ $2.41 Million |
-- |
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myel… Read more